The GDNF (Glial Cell Line-Derived Neurotrophic Factor) family represents a group of structurally related neurotrophic factors that play critical roles in the survival, maintenance, and regeneration of dopaminergic neurons. Originally discovered for their ability to promote the survival of embryonic dopaminergic neurons in vitro, these proteins have emerged as promising therapeutic candidates for neurodegenerative disorders, particularly Parkinson's disease (PD)[@lin1993]. The family includes GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN), each binding to specific receptor complexes that activate downstream signaling cascades essential for neuronal survival.
GDNF was first isolated from the rat B49 cell line based on its potent survival-promoting activity for embryonic dopaminergic neurons[@lin1993]. The protein is synthesized as a precursor molecule that undergoes proteolytic processing to produce the mature, biologically active homodimer. GDNF exhibits high affinity for the GDNF family receptor α1 (GFRα1), which serves as the primary receptor for GDNF signaling. The spatial and temporal expression pattern of GDNF in the brain includes the striatum, substantia nigra, and various cortical regions, where it supports dopaminergic neuron function throughout life.
The GDNF (Glial Cell Line-Derived Neurotrophic Factor) family represents a group of structurally related neurotrophic factors that play critical roles in the survival, maintenance, and regeneration of dopaminergic neurons. Originally discovered for their ability to promote the survival of embryonic dopaminergic neurons in vitro, these proteins have emerged as promising therapeutic candidates for neurodegenerative disorders, particularly Parkinson's disease (PD)[@lin1993]. The family includes GDNF, neurturin (NRTN), artemin (ARTN), and persephin (PSPN), each binding to specific receptor complexes that activate downstream signaling cascades essential for neuronal survival.
GDNF was first isolated from the rat B49 cell line based on its potent survival-promoting activity for embryonic dopaminergic neurons[@lin1993]. The protein is synthesized as a precursor molecule that undergoes proteolytic processing to produce the mature, biologically active homodimer. GDNF exhibits high affinity for the GDNF family receptor α1 (GFRα1), which serves as the primary receptor for GDNF signaling. The spatial and temporal expression pattern of GDNF in the brain includes the striatum, substantia nigra, and various cortical regions, where it supports dopaminergic neuron function throughout life.
Neurturin (NRTN) is the second member of the GDNF family to be characterized and shares approximately 40% sequence identity with GDNF[@kotzbauer1996]. NRTN binds preferentially to GFRα2, a receptor variant expressed predominantly in peripheral nervous system tissues and select brain regions. In the context of neurodegeneration, NRTN has demonstrated neuroprotective effects on dopaminergic neurons and has been investigated in preclinical models of Parkinson's disease. The NRTN-GFRα2 signaling axis participates in the maintenance of enteric neurons and parasympathetic ganglia, with emerging evidence suggesting roles in central nervous system plasticity.
Artemin (ARTN) and persephin (PSPN) represent the remaining members of the GDNF family, each with distinct expression patterns and receptor binding profiles. Artemin binds primarily to GFRα3, while persephin signals through GFRα4, though both can interact with alternative receptor complexes. These family members have been studied less extensively than GDNF and neurturin in the context of neurodegeneration, though PSPN has shown neuroprotective properties in models of motor neuron disease and Parkinson's disease[@milbrandt1998].
The GDNF family receptors (GFRα1-4) are glycosylphosphatidylinositol (GPI)-anchored proteins that lack transmembrane domains and function as ligands for the respective GDNF family members. Each GFRα receptor demonstrates specificity for particular GDNF family ligands, though cross-reactivity has been observed under certain conditions. The requirement for co-receptors in GDNF family signaling became apparent with the identification of RET (Rearranged during Transfection) as the canonical signal-transducing receptor for all GFRα-ligand complexes.
RET is a receptor tyrosine kinase that partners with all GFRα receptors to mediate the intracellular signaling of GDNF family ligands. Upon ligand binding to the GFRα-RET complex, RET undergoes dimerization and autophosphorylation at specific tyrosine residues, creating docking sites for downstream signaling effectors. The activation of RET triggers multiple intracellular signaling pathways, including the PI3K/AKT, MAPK/ERK, and PLCγ pathways, each contributing to the neurotrophic effects observed in target neurons[@bespalov2007].
The phosphoinositide 3-kinase (PI3K)/AKT pathway serves as a primary mediator of GDNF-induced neuronal survival. Following RET activation, PI3K is recruited to the plasma membrane where it generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3), leading to AKT activation through phosphorylation at Thr308 and Ser473. AKT subsequently phosphorylates multiple downstream targets, including BAD, FoxO transcription factors, and GSK-3β, promoting cell survival through inhibition of apoptotic pathways and enhancement of metabolic fitness[@bespalov2007].
In dopaminergic neurons, GDNF-mediated AKT activation has been shown to protect against multiple insults relevant to Parkinson's disease pathogenesis, including mitochondrial complex I inhibition, oxidative stress, and α-synuclein toxicity. The AKT pathway also contributes to synaptic plasticity and dopamine transporter function, suggesting roles in both neuroprotection and modulation of dopaminergic signaling.
The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway provides complementary survival signals following GDNF receptor activation. RET-mediated activation of Ras leads to sequential activation of RAF, MEK, and ERK kinases, with ERK1/2 translocating to the nucleus where it phosphorylates transcription factors including ELK-1, c-Fos, and CREB. This pathway contributes to long-term changes in gene expression that support neuronal differentiation, plasticity, and survival[@ibez2022].
The MAPK pathway interacts extensively with the PI3K/AKT pathway, with cross-talk occurring at multiple levels. ERK signaling can enhance PI3K/AKT signaling through phosphorylation of components of the survival pathway, while AKT can modulate MAPK signaling through effects on RAF activity. This network of interactions allows for integrated responses to GDNF signaling that are tailored to specific cellular contexts.
Phospholipase Cγ (PLCγ) activation represents an additional signaling branch downstream of GDNF receptor activation. PLCγ hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), leading to activation of protein kinase C (PKC) and release of calcium from intracellular stores. This pathway has been implicated in GDNF-induced neurite outgrowth and synaptic plasticity, with effects mediated through PKC isoforms and calcium-dependent signaling molecules.
The primary motivation for studying GDNF in neurodegeneration stems from its potent survival-promoting effects on dopaminergic neurons. Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the motor symptoms that define the disorder. GDNF and related family members can protect dopaminergic neurons from various insults that model key aspects of PD pathogenesis, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and mutant α-synuclein toxicity[@kells2004].
The neuroprotective effects of GDNF extend beyond direct survival promotion to include modulation of inflammation, support of mitochondrial function, and enhancement of autophagy. These multi-modal effects position GDNF family signaling as a comprehensive therapeutic approach that addresses multiple aspects of PD pathogenesis rather than single targets.
Multiple clinical trials have investigated GDNF delivery as a potential disease-modifying treatment for Parkinson's disease. Early open-label studies demonstrated promising results, with patients receiving intraputaminal GDNF infusion showing improvements in Unified Parkinson's Disease Rating Scale (UPDRS) scores and PET imaging markers of dopaminergic function[@nutt2007]. However, subsequent double-blind, placebo-controlled trials failed to demonstrate significant benefits, raising questions about optimal delivery methods, dosing, and patient selection.
Recent approaches have explored gene therapy using adeno-associated virus (AAV) vectors to deliver GDNF or neurturin to the striatum or substantia nigra. The CERE-120 trial, which used AAV-neurturin, demonstrated safety but did not meet its primary endpoint in a randomized controlled trial. Alternative delivery strategies, including intranasal administration and nanoparticle-encapsulated GDNF, remain under investigation as means to overcome the challenges of delivering large proteins across the blood-brain barrier.
GDNF signaling interacts with the pathological processes underlying α-synuclein aggregation, a hallmark of Parkinson's disease. Studies have demonstrated that GDNF can reduce α-synuclein aggregation in cellular models and enhance autophagy-mediated clearance of the protein. Conversely, α-synuclein aggregates can impair RET signaling and GDNF responsiveness, suggesting a bidirectional relationship where pathology both results from and contributes to neurotrophic factor signaling deficits[@cao2021].
The GDNF-PI3K-AKT pathway promotes mitochondrial biogenesis and function through multiple mechanisms, including activation of PGC-1α (PPARGC1A) and enhancement of mitochondrial DNA replication. Given that mitochondrial dysfunction represents a central contributor to dopaminergic neuron vulnerability in PD, the ability of GDNF to support mitochondrial health contributes significantly to its neuroprotective effects. The pathway also protects against mitochondrial apoptosis through phosphorylation and inactivation of pro-apoptotic proteins like BAD.
Microglial activation and neuroinflammation play important roles in PD progression. GDNF signaling can modulate neuroinflammation through effects on microglial activation state, with evidence suggesting that GDNF can shift microglia toward a more protective phenotype. Additionally, the anti-apoptotic signals activated by GDNF can protect neurons from inflammation-induced cell death, providing a multi-pronged approach to neurodegeneration that addresses both cell-autonomous and non-cell-autonomous mechanisms.
The development of small molecule agonists that can activate GFRα receptors or RET directly represents an active area of drug discovery. Such compounds would overcome the delivery challenges associated with protein therapeutics and potentially provide more consistent signaling than intermittent protein administration. Several research groups have identified RET agonists and GFRα-modulating compounds, though none have yet reached clinical development for neurodegenerative indications.
Gene therapy using viral vectors provides a potentially durable solution for GDNF delivery to the brain. AAV vectors can be engineered to express GDNF under neuronal promoters, allowing targeted expression in dopaminergic neurons. Clinical trials have evaluated AAV-GDNF delivery to the substantia nigra and striatum, with ongoing research focused on optimizing vector design, expression levels, and surgical delivery methods.
Cell transplantation strategies have explored the use of cells engineered to secrete GDNF as a sustained delivery platform. Mesenchymal stem cells (MSCs) modified to express GDNF have demonstrated neuroprotective effects in preclinical PD models and represent an alternative approach that combines cell replacement with trophic factor support.
| Protein/Gene | Function | Relevance |
|-------------|----------|-----------|
| [GDNF](/genes/gdnf) | Primary ligand for GFRα1/RET | Dopaminergic neuron survival |
| [NRTN](/genes/nrtn) | Ligand for GFRα2/RET | Peripheral and CNS neuroprotection |
| [GFRα1](/proteins/gfro1-protein) | Primary receptor for GDNF | Ligand binding and complex formation |
| [RET](/proteins/ret-protein) | Signal-transducing receptor | Tyrosine kinase signaling |
| [AKT1](/genes/akt1) | Key survival kinase | PI3K/AKT pathway effector |
| [MAPK1](/genes/mapk1) | ERK2 kinase | MAPK pathway signaling |
| [PPARGC1A](/genes/ppargc1a) | Mitochondrial biogenesis regulator | Energy metabolism |
The direct delivery of GDNF protein to the brain has been explored through multiple routes, each presenting distinct challenges and opportunities:
Viral vector-mediated gene therapy provides a potentially durable solution for continuous GDNF expression:
Small molecule approaches target either RET tyrosine kinase or GFRα receptors:
| Biomarker | Source | Relevance |
|-----------|--------|-----------|
| GDNF levels | Serum, CSF | Target engagement marker |
| Neurturin | CSF | Pharmacodynamic indicator |
| RET phosphorylation | PBMCs | Mechanistic biomarker |
| YKL-40 | CSF, serum | Neuroinflammation monitoring |
| Neurofilament light chain (NfL) | Serum, CSF | Disease progression marker |
| Trial | Phase | Intervention | Status | Outcomes |
|-------|-------|--------------|--------|----------|
| AAV-GDNF (various) | I/II | Gene therapy | Completed | Safety, preliminary efficacy |
| CERE-120 (AAV-NRTN) | II | Gene therapy | Completed | Primary endpoint not met |
| Intranasal GDNF | I | Protein | Recruiting | Safety, bioavailability |
| GDNF-meso cells | I/II | Cell therapy | Ongoing | Safety, engraftment |
GDNF-based therapies aim to provide:
Neurotrophic factor therapy may benefit non-motor aspects:
Unlike symptomatic treatments, GDNF therapy aims to:
The GDNF family of neurotrophic factors represents one of the most promising therapeutic approaches for Parkinson's disease, with strong preclinical evidence supporting neuroprotection of dopaminergic neurons. While clinical translation has proven challenging, ongoing research into delivery methods, small molecule agonists, and gene therapy continues to advance the field. The integration of GDNF signaling with understanding of other PD mechanisms—including α-synuclein pathology, mitochondrial dysfunction, and neuroinflammation—suggests that combination approaches targeting multiple pathways may prove most effective for disease modification.